Information on selecting the most advantageous offer - request for proposal number RFP 021565 – GLP HERG INHIBITION ASSAY IN IN VITRO CONDITIONS

In connection with obtaining from the National Centre for Research and Development a grant for the project "Clinical development of an innovative anti-cancer drug using the mechanism of reactivation of p53 protein" (project no. MAZOWSZE/0012/19) under R&D programme "Ścieżka dla Mazowsza", acting on the basis of Article 10 of the financial project support contract, Adamed Pharma S.A. informs that the contract will be awarded to the following company that have presented the most advantageous offer:

• Pharmaron, Inc.201 East Jefferson StreetLouisville, KY 40202